T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma

N. Brudno, Jennifer; Marić, Irina; D. Hartman, Steven; J. Rose, Jeremy; Wang, Michael; Lam, Norris; Stetler‐Stevenson, Maryalice; Salem, Dalia; M. Yuan, Constance; Z. Pavletic, Steven; A. Kanakry, Jennifer; Abbas Ali, Syed; Mikkilineni, Lekha; A. Feldman, Steven; F. Stroncek, David; Hansen, Brenna; Lawrence, Judith; Patel, Rashmika; T. Hakim, Frances; E. Gress, Ronald; N. Kochenderfer, James

doi:10.1200/jco.2018.77.8084

Public

T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma

Published in Journal of Clinical Oncology • May 29, 2018

Authors:

Jennifer N. Brudno

Irina Marić

Steven D. Hartman

Abstract

Purpose Therapies with novel mechanisms of action are needed for multiple myeloma (MM). T cells can be genetically modified to express chimeric antigen receptors (CARs), which are artificial proteins that target T cells to antigens. B-cell maturation antigen (BCMA) is expressed by normal and maligna...

Subject

Medicine

Chimeric antigen receptor

Multiple myeloma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!